Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase 3b/4 Study of Baricitinib vs TNF Inhibitors in Rheumatoid Arthritis
2018-003351-37Phase 3Unknown
- Sponsor
- Eli Lilly and Company
- Start
- May 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of baricitinib in rheumatoid arthritis (RA) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Time to first VTE event. Status: unknown.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2018-003351-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003351-37.